Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes

Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people... Diabetologia (2017) 60:1620–1629 DOI 10.1007/s00125-017-4337-9 REVIEW Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes 1,2 1 1 Simon J. Griffin & James K. Leaver & Greg J. Irving Received: 21 April 2017 /Accepted: 24 May 2017 /Published online: 2 August 2017 The Author(s) 2017. This article is an open access publication Abstract control. Summary estimates were based on a small number of Aims/hypothesis Metformin is the most-prescribed oral med- events: 416 myocardial infarctions/ischaemic heart disease ication to lower blood glucose worldwide. Yet previous sys- events in seven studies and 111 strokes in four studies. The tematic reviews have raised doubts about its effectiveness in UK Prospective Diabetes Study (UKPDS) contributed the ma- reducing risk of cardiovascular disease, the most costly com- jority of data to the summary estimates, with weights ranging plication of type 2 diabetes. We aimed to systematically iden- from 52.3% for myocardial infarction to 70.5% for stroke. All tify and pool randomised trials reporting cardiovascular out- outcomes, with the exception of stroke, favoured metformin, comes in which the effect of metformin was ‘isolated’ through with limited heterogeneity between studies, but none achieved comparison to diet, lifestyle or http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Diabetologia Springer Journals

Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes

Loading next page...
 
/lp/springer_journal/impact-of-metformin-on-cardiovascular-disease-a-meta-analysis-of-3boWq0f60O
Publisher
Springer Berlin Heidelberg
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine; Metabolic Diseases; Human Physiology
ISSN
0012-186X
eISSN
1432-0428
D.O.I.
10.1007/s00125-017-4337-9
Publisher site
See Article on Publisher Site

Abstract

Diabetologia (2017) 60:1620–1629 DOI 10.1007/s00125-017-4337-9 REVIEW Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes 1,2 1 1 Simon J. Griffin & James K. Leaver & Greg J. Irving Received: 21 April 2017 /Accepted: 24 May 2017 /Published online: 2 August 2017 The Author(s) 2017. This article is an open access publication Abstract control. Summary estimates were based on a small number of Aims/hypothesis Metformin is the most-prescribed oral med- events: 416 myocardial infarctions/ischaemic heart disease ication to lower blood glucose worldwide. Yet previous sys- events in seven studies and 111 strokes in four studies. The tematic reviews have raised doubts about its effectiveness in UK Prospective Diabetes Study (UKPDS) contributed the ma- reducing risk of cardiovascular disease, the most costly com- jority of data to the summary estimates, with weights ranging plication of type 2 diabetes. We aimed to systematically iden- from 52.3% for myocardial infarction to 70.5% for stroke. All tify and pool randomised trials reporting cardiovascular out- outcomes, with the exception of stroke, favoured metformin, comes in which the effect of metformin was ‘isolated’ through with limited heterogeneity between studies, but none achieved comparison to diet, lifestyle or

Journal

DiabetologiaSpringer Journals

Published: Aug 2, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off